Loading company…
Promedior developed therapies for serious diseases, with a focus on regenerative medicine and immune modulation.
Founded in 2006 and based in Lexington, US, Promedior developed therapeutic candidates for serious diseases, including conditions involving immune response and tissue regeneration. Bristol-Myers Squibb Company acquired the company in August 2015 for an upfront USD 150 mn, with potential total payments of USD 1.25 billion. Promedior had completed eight deals by the time of the acquisition.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in